Mineralys Therapeutics (MLYS) Cash from Financing Activities (2022 - 2026)

Mineralys Therapeutics has reported Cash from Financing Activities for 5 years, with the latest figure at $24.3 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 87.18% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $426.0 million (up 125.14% YoY) and the FY2025 annual result came in at $591.0 million, up 408.86% from the prior year.
• Cash from Financing Activities slipped to $24.3 million in Q1 2026 per MLYS's latest filing, from $96.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $295.2 million in Q3 2025 and troughed at -$1.1 million in Q4 2022.
• A 5-year average of $62.5 million and a median of $9.8 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 100.54% in 2024, then jumped 29518900.0% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$1.1 million in 2022, then surged by 106.93% to $74000.0 in 2023, then gained by 21.62% to $90000.0 in 2024, then jumped by 107345.56% to $96.7 million in 2025, then sank by 74.9% to $24.3 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $24.3 million, $96.7 million, and $295.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.